It is obvious that the risks presented by the novel coronavirus (COVID-19) transcend "business as usual" for market participants. How should Boards be approaching the risks and opportunities presented by the situation to satisfy their "Caremark" duties and ensure the appropriate risk management processes and response plans are in place?